ARROTEX Pharmaceuticals has announced a strategic partnership with Boehringer Ingelheim to have the exclusive Australian reseller rights to respiratory products Spiriva (tiotropium 18 micrograms powder for inhalation) and Spiriva HandiHaler.
Following last year's merger of Apotex Australia and Arrow Pharmaceuticals, Arrotex now promotes GSK's Seretide, Pavtide (Seretide authorised generic), Flixotide and Ventolin CFC Inhaler brands, along with AstraZeneca's respiratory brands Symbicort Turbuhaler, Symbicort Rapihaler, Pulmicort, Omnaris, Alvesco, Bricanyl and Oxis.
Arrotex CCO, Lisa Golden, said the business was committed to creating value for community pharmacies, adding the Spiriva deal would "provide unique branded portfolio offerings for pharmacy to unlock additional revenue".
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Feb 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Feb 20
